Anti-Obesity Drug · Tyr-hGH(177-191)
HGH fragment for targeted fat burning — no anabolic effects.
FDA
Research Only
WADA
Not Listed
HALF-LIFE
~30 minutes
ROUTE
SubQ injection or oral
SCHEDULE
Daily
In Plain English
HGH fragment for targeted fat burning — no anabolic effects.
Status & Legality
NATTY?
No Test ExistsNo established test exists for this compound.
FDA
Research OnlyFor research purposes only. Not FDA approved.
WADA
Not ListedNot currently on WADA prohibited list.
COMPOUNDING
Not from pharmaciesNot available from licensed compounding pharmacies.
PRESCRIBED
Not prescribedNot prescribed in conventional medicine.
ROUTE
SubQ injection or oralAdministration via subq injection or oral.
Fat loss
Lipolysis
Metabolism
Cartilage repair
AOD-9604 is a modified fragment of human growth hormone (amino acids 177–191) that retains the lipolytic (fat-burning) properties of HGH without anabolic or blood sugar effects. It stimulates fat cell breakdown and inhibits lipogenesis. Gained TGA approval in Australia as a food ingredient.
Generally very well tolerated
Injection site irritation
Mild hypoglycemia (very rare)
Headache (uncommon)
Expecting dramatic fat loss without caloric control — AOD-9604 enhances lipolysis but does not override dietary excess
Not injecting fasted — eating before the injection blunts the lipolytic response significantly
Comparing results to GLP-1 agonists — AOD-9604 has modest, targeted effects; GLP-1s are more potent for total weight loss
GLP-1 agonists (semaglutide) — can be combined for dual fat loss mechanisms; different pathways
Insulin — monitor glucose during fasted injections, though hypoglycemia risk is very low with this compound
GH secretagogues — generally synergistic; commonly combined in fat loss protocols
AOD-9604 is a clean, targeted fat-burning peptide — none of the anabolic or glucose effects of full HGH, just the lipolytic fragment. Results are real but subtle compared to GLP-1s. Best used as an adjunct during body recomposition rather than a primary weight loss tool. Fasted AM injection is non-negotiable.
Stats
Sources & Studies
Heffernan M. et al., Endocrine, 2001